biote Corp.

biote Corp. (Nasdaq: BTMD) is a hormone health company that completed its de-SPAC business combination with Haymaker Acquisition Corp. III in 2022, with the blank-check vehicle having priced its initial public offering in 2021. The SPAC was sponsored by Haymaker Partners. Operating in the healthcare sector, biote specializes in subcutaneous hormone pellet optimization therapy delivered through a nationwide network of certified medical practitioners. The company filed an 8-K current report with the Securities and Exchange Commission on May 24, 2024, under accession number 0001193125-24-146528. For full filing history, post-merger financials, and SPAC analytics on BTMD and thousands of other transactions, sign up for complete data on SpacDesk.